This company has been acquired

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Tyme Technologies jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:TYME - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2022	N/A	-24	-20	-20	N/A
3/31/2022	N/A	-24	-21	-21	N/A
12/31/2021	N/A	-24	-19	-19	N/A
9/30/2021	N/A	-25	-21	-21	N/A
6/30/2021	N/A	-26	-23	-23	N/A
3/31/2021	N/A	-29	-24	-24	N/A
12/31/2020	N/A	-28	-24	-24	N/A
9/30/2020	N/A	-28	-23	-23	N/A
6/30/2020	N/A	-28	-20	-20	N/A
3/31/2020	N/A	-22	-20	-20	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-29	-19	-19	N/A
6/30/2019	N/A	-29	-19	-19	N/A
3/31/2019	N/A	-33	-20	-20	N/A
12/31/2018	N/A	-27	-20	-20	N/A
9/30/2018	N/A	-25	-17	-17	N/A
6/30/2018	N/A	-23	-15	-15	N/A
3/31/2018	N/A	-19	-12	-12	N/A
12/31/2017	N/A	-17	-10	-10	N/A
9/30/2017	N/A	-14	-9	-9	N/A
6/30/2017	N/A	-12	-7	-7	N/A
3/31/2017	N/A	-15	-6	-6	N/A
12/31/2016	N/A	-17	-6	-6	N/A
6/30/2016	N/A	-13	-6	-6	N/A
3/31/2016	N/A	-11	N/A	-5	N/A
12/31/2015	N/A	-12	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if TYME's forecast earnings growth is above the savings rate (1.9%).

Ertrag vs. Markt: Insufficient data to determine if TYME's earnings are forecast to grow faster than the US market

Hohe Wachstumserträge: Insufficient data to determine if TYME's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if TYME's revenue is forecast to grow faster than the US market.

Hohe Wachstumseinnahmen: Insufficient data to determine if TYME's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if TYME's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Tyme Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to US$9.44

Recent updates

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from NASDAQ Composite Index

Tyme Technologies, Inc. Announces Board Changes

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

TYME stock surges on merger agreement and Syros Pharmaceuticals

Tyme Technologies Receives Extension to Regain Compliance with the Nasdaq Continued Listing Standards

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Insufficient new directors

Insufficient new directors

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Tyme Technologies, Inc. to Report Q3, 2022 Results on Feb 11, 2022

Tyme Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Tyme Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections

Tyme Technologies Offers Incredible Risk-Reward

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Co-Founder notifies of intention to sell stock

TYME Technologies, Inc. Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

Independent Director recently bought US$52k worth of stock

Tyme Technologies: The Market Missed The Bullish Memo

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from Russell 3000 Growth Index

Tyme Technologies reports FY results

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

Co-Founder notifies of intention to sell stock

Price target increased to US$9.44

Chief Medical Officer has left the company

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Insider recently sold US$55k worth of stock

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Insider recently sold US$55k worth of stock

Tyme falls after equity offer as quarterly data indicate liquidity pressure

New 90-day high: US$3.53

Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

Co-Founder notifies of intention to sell stock

New 90-day high: US$1.34

Revisiting Tyme Technologies

Co-Founder recently sold US$613k worth of stock

Co-Founder notifies of intention to sell stock

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

Tyme Technologies, Inc. Announces Executive Changes

New 90-day high: US$1.05

Tyme Technologies names new finance chief

Tyme Technologies, Inc. Announces Resignation of Ben R. Taylor as Chief Financial Officer

New 90-day low: US$0.92

Co-Founder notifies of intention to sell stock

Tyme Technologies, Inc. Announces Executive Changes

New 90-day low - US$0.98

New 90-day low - US$1.17

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken